11 December 2024
11 December 2024
GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.
Updated figures from the WHO show that more than one in five adults aged between 15 and 49 globally have the infection.
While 88.1% of patients completed one cycle, patient adherence beyond the fourth cycle was relatively low.
Relation will obtain a $45m upfront payment from GSK, including a $15m equity investment.
Greenberg is set to lead the company as it progresses with the clinical development of its orally inhaled treatment, flecainide.
The topline results from the Phase III trial found the treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.
As of 2020, the only product marketed for RSV prophylaxis was AstraZeneca/AbbVie's Synagis.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
